In a report published Monday, Bank of America reiterated a Neutral rating on Amgen AMGN, and raised its price objective from $97 to $99.
Bank of America wrote, "This weekend, AFFY/Takeda announced they were recalling all lots of their erythropoesis stimulating agent (ESA) Omontys from the market due to serious hypersensitivity reactions associated with the first infusion (0.2% total hypersensitivity, including approx 5 deaths). All patients previously taking Omontys are instructed to discontinue use. This news follows dialysis provider Fresenius' decision <2 weeks ago to close the Omontys pilot program. As we mentioned at that time, our AMGN model assumed Omontys as the preferred ESA at Fresenius starting in April. Given the recall, we are now increasing AMGN's ESA share in our model (2013 Epogen sales from $1.54B to $1.82B), bringing our total 2013 revenue up to $18.4B, and we view AMGN's 2013 $17.8-$18.2B revenue guidance as overly conservative."
Amgen closed Friday at $86.82.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in